WO2007055682A8 - Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides - Google Patents

Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides

Info

Publication number
WO2007055682A8
WO2007055682A8 PCT/US2005/040215 US2005040215W WO2007055682A8 WO 2007055682 A8 WO2007055682 A8 WO 2007055682A8 US 2005040215 W US2005040215 W US 2005040215W WO 2007055682 A8 WO2007055682 A8 WO 2007055682A8
Authority
WO
WIPO (PCT)
Prior art keywords
immunostimulatory
oligonucleotide
based compounds
dinucleotides
modified
Prior art date
Application number
PCT/US2005/040215
Other languages
French (fr)
Other versions
WO2007055682A2 (en
Inventor
Sudhir Agrawal
Dong Yu
Ekambar R Kandimalla
Original Assignee
Idera Pharmaceuticals
Sudhir Agrawal
Dong Yu
Ekambar R Kandimalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals, Sudhir Agrawal, Dong Yu, Ekambar R Kandimalla filed Critical Idera Pharmaceuticals
Priority to PCT/US2005/040215 priority Critical patent/WO2007055682A2/en
Priority to JP2008538854A priority patent/JP2009514525A/en
Priority to CA002630118A priority patent/CA2630118A1/en
Priority to AU2005338050A priority patent/AU2005338050B2/en
Priority to CNA2005800524839A priority patent/CN101351469A/en
Priority to EP05851389A priority patent/EP1945653A4/en
Priority to MX2008006004A priority patent/MX2008006004A/en
Publication of WO2007055682A2 publication Critical patent/WO2007055682A2/en
Publication of WO2007055682A8 publication Critical patent/WO2007055682A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
PCT/US2005/040215 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides WO2007055682A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PCT/US2005/040215 WO2007055682A2 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
JP2008538854A JP2009514525A (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds, including modified immunostimulatory dinucleotides
CA002630118A CA2630118A1 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
AU2005338050A AU2005338050B2 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CNA2005800524839A CN101351469A (en) 2005-11-07 2005-11-07 Immune stimulation specialty of compound containing modified immune irritation dinucleotide base on oligonucleotide
EP05851389A EP1945653A4 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
MX2008006004A MX2008006004A (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/040215 WO2007055682A2 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides

Publications (2)

Publication Number Publication Date
WO2007055682A2 WO2007055682A2 (en) 2007-05-18
WO2007055682A8 true WO2007055682A8 (en) 2007-08-02

Family

ID=38023708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/040215 WO2007055682A2 (en) 2005-11-07 2005-11-07 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides

Country Status (7)

Country Link
EP (1) EP1945653A4 (en)
JP (1) JP2009514525A (en)
CN (1) CN101351469A (en)
AU (1) AU2005338050B2 (en)
CA (1) CA2630118A1 (en)
MX (1) MX2008006004A (en)
WO (1) WO2007055682A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CN106535876B (en) 2014-06-04 2020-09-11 埃克西奎雷股份有限公司 Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP2017537619A (en) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes
WO2017193087A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2004064782A2 (en) * 2003-01-16 2004-08-05 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
KR101138131B1 (en) * 2003-12-08 2012-04-23 이데라 파마슈티칼즈, 인코포레이티드 Modulation of immunostimulatory properties by small oligonucleotide-based compounds

Also Published As

Publication number Publication date
AU2005338050B2 (en) 2012-02-02
WO2007055682A2 (en) 2007-05-18
EP1945653A4 (en) 2012-03-14
CN101351469A (en) 2009-01-21
MX2008006004A (en) 2008-10-01
AU2005338050A1 (en) 2007-05-18
AU2005338050A8 (en) 2008-07-03
JP2009514525A (en) 2009-04-09
EP1945653A2 (en) 2008-07-23
CA2630118A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2007055682A8 (en) Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP1601789A4 (en) Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
IL256157A (en) Method of preparing isolated modified uricase
EP1874345A4 (en) Immunostimulatory compositions
GB0607634D0 (en) Set of connectors
EP1854467B8 (en) Immunostimulatory composition
AU2007308141A1 (en) Methods of treating oral mucositis
ZA200805079B (en) Immunostimulatory compositions and methods
IL192088A (en) Compositions comprising an immune-stress-reducing enzyme
EP1834462A4 (en) Clipping of transmission signal
AU2005903848A0 (en) Modification of flavonoid biosynthesis
AU2005901939A0 (en) Treatment of Foodstuffs
AU2005906132A0 (en) Uses of Yin Yang-1
AU2005904577A0 (en) Methods of Altering Poppy Characteristics
AU2003906658A0 (en) Modulation of Hyaluronan Synthase
AU2003905551A0 (en) Modulation of Hyaluronan Synthase
AU2006901582A0 (en) Amplification of DNA fragments
AU2005906585A0 (en) Methods and Preparation of Uses of Xanthorrhoeaceae Compositions
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases
AU2004905501A0 (en) Methods of dispersion
AU2005901749A0 (en) Improved production of titana
AU2004907178A0 (en) Transfer of molecules
AU2005901688A0 (en) Novel derivatives of multi-functional molecules
AU2005904981A0 (en) Compositions and methods of using same
AU2005904259A0 (en) Compositions and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005851389

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005338050

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2008538854

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2630118

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/006004

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2005338050

Country of ref document: AU

Date of ref document: 20051107

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2069/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580052483.9

Country of ref document: CN